E
CMPI

Ergoteles’s Checkmate Pharmaceuticals, Inc. Common Stock CMPI Stock Holding History

Ergoteles’s Portfolio CMPI Stock Details CMPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-25,870
Closed -$103K – 1749
2021
Q3 		$103K Sell
25,870
-557
-2% -$2.87K ﹤0.01% 1102
2021
Q2 		$158K Buy
+26,427
New +$187K ﹤0.01% 1342

Other funds holding CMPI

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Ergoteles's CMPI Position: Q4 2021 in Review

Ergoteles sold out of Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) in Q4 2021, closing a stake of 25,870 shares — an estimated $103K sold.

Ergoteles first reported a position in CMPI in Q2 2021 and held it in 2 quarters. The position peaked at $158K in Q2 2021. 25 funds tracked by Wall St. Rank hold CMPI as of Q4 2021.

  • Ergoteles reported no remaining Checkmate Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Ergoteles sold 25,870 Checkmate Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $103K.
  • Ergoteles first reported a position in Checkmate Pharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Ergoteles's Checkmate Pharmaceuticals, Inc. Common Stock position peaked at $158K in Q2 2021.
  • 25 funds tracked by Wall St. Rank held Checkmate Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Ergoteles's 13F filing for Q4 2021, filed 14 Feb 2022.